More than 110 distribution partners gathered at MSD Animal Health's Madrid headquarters for the first Spanish meeting on Nobivac NXT. Spain has nearly five million registered cats, and around one in five still does not receive vaccination.
The company presented the product's scientific basis and its proposed value for veterinary clinics. The Madrid meeting is the first stage of a wider rollout, with veterinarians and distributors basic to the effort. Cat owners are also part of the plan.
A separate feline-medicine session in Madrid on 23 September, involving MSD Animal Health España and IVC Evidensia España, included Susana Domínguez’s presentation, “Nobivac NXT: El nuevo referente en vacunación felina”. The programme covered vaccination and oncology, as well as dentistry. Other sessions addressed cough, endoscopy and CT.
Feline medicine now takes up more space in Spain's companion-animal sector, but a prevention gap remains. More cats could receive vaccines, and clinics have room to tailor preventive care more closely to feline needs.
Federica Burgio, Scientific Lead in the Companion Animal team at MSD Animal Health España, led the scientific presentation. She explained Nobivac NXT and the science behind the new preventive-care range, with immunology at the centre of the launch.
Marisa Palmero, DVM, also joined the programme. She is accredited in Feline Medicine by AVEPA and European Certified in Feline Medicine by ESPVS. Her session, titled "Vacunación felina hoy", covered the development of feline prevention and the clinical challenges linked to cats today.
Sandra Castillo, MSD Animal Health's Spanish Companion Animal director, presented the launch as part of a strategic category for the company. She connected the science with daily veterinary work and described Nobivac NXT as a next-generation preventive option for veterinary professionals and cat owners. That message reflects the product's wider public positioning: a new generation of feline prevention based on new technology and current needs in feline medicine.
The organisers also scheduled a practical business session. Javier Fuentes Ibáñez of specialist company NCompany led a workshop on artificial intelligence, using practical cases and roleplaying exercises based on situations in veterinary clinics.
The focus on immunology reflects broader interest in how biological information can guide medical decisions, as explored in earlier blood research. Nobivac NXT remains a feline vaccination product. The comparison does not change its scope, but helps explain why the scientific case sits at the centre of the company's presentation.
The rollout will continue with a regional media meeting in Poland during WSAVA on 13 October and a national Madrid event on 11 November. A launch webinar is set for 26 November. MSD Animal Health also plans appearances at Vetcan from 22 to 24 October and Congreso Andaluz from 6 to 7 November. VetCats is scheduled for 12 to 14 November, followed by SEVC from 19 to 21 November. These dates place the Spanish launch within a wider European campaign in autumn 2026.
Distributors and media meetings anchor the rollout, alongside congress appearances and online education. The scientific proposition is intended to help clinics reach cats outside routine vaccination; the product's value will depend on how well it reaches those animals.